Cerus Signs INTERCEPT Platelet Agreements With Two Key Blood Component Suppliers in Germany and Aust
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NAS: CERS) announced today that the TILAK, University Clinics, Regional Hospital Innsbruck (LKI) in Austria and ZIT GmbH Hamburg in Germany, ...
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today the successful outcome of a multi-year trial of INTERCEPT-treated platelet components conducted at the Swiss Red ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results